There were 1,763 press releases posted in the last 24 hours and 426,967 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image